Hers vs Oak Longevity: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
Oak Longevity beats Hers overall, scoring 7.5/10 vs 7.3/10. Oak Longevity is more affordable at $130/mo vs $199/mo. Choose Hers for women who want brand-name wegovy (injection or pill) at $149. Choose Oak Longevity for budget-conscious users who want one of the cheapest compound.
A side-by-side comparison of Hers and Oak Longevity covering pricing, scores, medication types, insurance, and more to help you decide.
Hers
#31 of 42The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.
Visit HersOak Longevity
#23 of 42Telehealth platform offering compounded semaglutide and tirzepatide at the lower end of market pricing, alongside an oral Wegovy option, brand-name FDA-approved GLP-1s, and a longevity stack (NAD+, Glutathione, Sermorelin, Tesamorelin). Distinctive non-subscription billing — patients pay each month manually rather than auto-renew.
Visit Oak Longevity| Feature | Hers | Oak Longevity |
|---|---|---|
| Our Score | 7.3/10 | 7.5/10 |
| Starting Price | $199/mo | $130/mo |
| Medication Type | Both | Both |
| Insurance Accepted | No | No |
| Best For | Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand | Budget-conscious users who want one of the cheapest compounded GLP-1 entries plus a no-subscription billing model and a longevity-stack add-on (NAD+, Sermorelin) |
| Ranking | #31 | #23 |
Pros & Cons Compared
Hers
Pros
- +2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
- +Zepbound access via the Lilly/Hims-Hers partnership announced 2026
- +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
- +Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services
Cons
- −Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
- −Generic support experience — large patient volume means less personalized attention
- −Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
- −Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value
Oak Longevity
Pros
- +$130/mo for compounded semaglutide is among the cheapest entries on the market — Sprout Health ($99) and Sesame Care ($99) are lower, but Oak undercuts most mid-tier platforms
- +Compounded tirzepatide at $199/mo is competitively priced for a GLP-1+GIP dual agonist
- +No-subscription model — patients are not auto-charged each month, choose to renew manually. Reduces unwanted recurring charges
- +Broadest medication mix on the platform: compounded sema + tirz, oral Wegovy, brand Wegovy/Ozempic/Zepbound/Mounjaro, plus longevity peptides (NAD+, Glutathione, Sermorelin, Tesamorelin)
- +Money-back guarantee if not approved by physician — useful safety net for borderline-eligibility patients
- +Free shipping and free health coaching included in every program
Cons
- −Brand-name pricing ($1,200-$1,500/mo) is significantly above market — NovoCare direct pricing for Wegovy is $349/mo, LillyDirect Zepbound $299/mo. Never buy brand-name through Oak
- −No published lab panels, no specialty (obesity medicine) physicians disclosed — clinical depth is shallow
- −'Up to 50% cheaper than competitors' marketing claim is unverified and inconsistent — depends on which competitor and which medication tier
- −'Longevity' framing pushes users toward add-on products (NAD+, Sermorelin, Tesamorelin) that have limited clinical evidence for weight loss specifically
- −Newer brand without disclosed company history, founding date, or executive team on landing pages
- −Three-month plans are billed upfront — pricing transparency is good, but commit-up-front is a friction point for users testing the platform
Our Verdict
Oak Longevity edges out Hers with a score of 7.5/10 vs 7.3/10. If budget is your priority, Oak Longevity starts at $130/mo compared to Hers's $199/mo. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand. Choose Oak Longevity if you want: budget-conscious users who want one of the cheapest compounded glp-1 entries plus a no-subscription billing model and a longevity-stack add-on (nad+, sermorelin).